AbbVie (ABBV) Earnings Analysis

AbbVie (ABBV) next reports earnings on 2026-07-31, consensus EPS 3.62 USD. Last quarter (2026-02-04) it beat with EPS 2.71 USD vs 2.65 USD est (+2.3%). It has beaten estimates in 6/7 recent quarters (86%). Trailing P/E 124.20.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ABBV next report earnings?

Next earnings date2026-07-31
Consensus EPS estimate3.62 USD
Revenue estimate16.79B

ABBV earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-042.71 USD2.65 USD+2.3%Beat
2025-10-311.86 USD1.77 USD+5.1%Beat
2025-07-312.97 USD2.88 USD+3.1%Beat
2025-04-252.46 USD2.38 USD+3.4%Beat
2025-01-312.16 USD2.98 USD-27.5%Miss
2024-10-303 USD2.92 USD+2.7%Beat
2024-07-252.65 USD2.57 USD+3.1%Beat

Beat rate: 6/7 (86%) over reported quarters with consensus data.

ABBV valuation and analyst view

Trailing P/E124.20
Trailing EPS2.051 USD
Price / book16.34
Dividend yield2.70%
Market cap450.46B
Analyst consensusBuy (29 buy / 11 hold / 1 sell)
Avg price target275.92 USD

Related research pages

Frequently asked questions

When is AbbVie (ABBV)'s next earnings date?

AbbVie is next scheduled to report on 2026-07-31, with a consensus EPS estimate of 3.62 USD and revenue estimate of 16.79B.

Did ABBV beat earnings last quarter?

In its 2026-02-04 report, ABBV posted EPS of 2.71 USD versus a 2.65 USD estimate — a beat of 2.3%.

What is ABBV's earnings track record?

Over the last 7 reported quarters with consensus data, ABBV beat estimates 6 times (86%).

What is ABBV's current P/E ratio and EPS?

ABBV trades at a trailing P/E of 124.20 on trailing EPS of 2.051453775486734 USD.

What do analysts rate ABBV?

Analyst consensus is "Buy" across 41 ratings (0 strong buy, 29 buy, 11 hold, 1 sell, 0 strong sell). Average 12-month price target: 275.92 USD.